for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cerus Corporation

CERS.OQ

Latest Trade

4.47USD

Change

0.02(+0.45%)

Volume

225,416

Today's Range

4.39

 - 

4.55

52 Week Range

4.29

 - 

7.06

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.45
Open
4.41
Volume
225,416
3M AVG Volume
18.64
Today's High
4.55
Today's Low
4.39
52 Week High
7.06
52 Week Low
4.29
Shares Out (MIL)
140.32
Market Cap (MIL)
624.43
Forward P/E
-9.14
Dividend (Yield %)
--

Latest Developments

More

Cerus Corp Reports Q2 Loss Per Share $0.13

Cerus Corporation Q1 Loss Per Share $0.14

Cerus Says Entered Into Credit Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Industry

Biotechnology & Drugs

Contact Info

1220 Concord Ave Ste 600

+1.925.2886000

http://www.cerus.com/

Executive Leadership

Daniel N. Swisher

Independent Chairman of the Board

William M. Greenman

President, Chief Executive Officer, Director

Kevin Dennis Green

Chief Financial Officer, Vice President - Finance

Carol M. Moore

Senior Vice President - Regulatory Affairs, Quality and Clinical

William Moore

Senior Vice President of Manufacturing Operations and Supply Chain

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.620

2017

-0.560

2018

-0.440

2019(E)

-0.487
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.43
Price To Book (MRQ)
9.50
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
66.77
LT Debt To Equity (MRQ)
59.92
Return on Investment (TTM)
-53.91
Return on Equity (TTM)
-40.89

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up